Background: Abiraterone and docetaxel are both approved treatments for men with metastatic castration-resistant prostate cancer (mCRPC). Abiraterone pre-docetaxel is currently undergoing evaluation in a phase III study. In vitro studies indicate that taxanes may act by disrupting androgen receptor signalling. We hypothesised that prior abiraterone exposure would adversely impact docetaxel efficacy.
introduction
Prostate cancer is the most prevalent cancer in men [1] and the second leading cause of male cancer-related deaths [2] . In TAX327, reported in 2004, the combination of three-weekly docetaxel and prednisone showed a median 2.4-month improvement in overall survival (OS) when compared with mitoxantrone and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) [3] . Docetaxel is a semi-synthetic taxane that irreversibly binds to β-actin, altering microtubule polymerisation dynamics, impacting cell mitosis and interphase microtubule function and thus triggering apoptosis [4] . Moreover, several recent studies have reported that tubulin-targeting drugs cause cytoplasmic androgen receptor (AR) sequestration ex vivo [5, 6] and in circulating tumour cells [7] , significant down-regulation of AR and prostate-specific antigen (PSA) expression and nuclear accumulation of the forkhead transcription factor family member FOXO1, a potent repressor of AR function [8, 9] . Overall, these studies provide strong in vitro evidence that the antitumour activity of docetaxel is at least in part associated with disruption of AR signalling.
Several studies have now confirmed that AR signalling remains a key driver in mCRPC, including the recent clinical studies of abiraterone acetate (abiraterone) [10, 11] . Abiraterone is a potent and selective small-molecule inhibitor of CYP17A1, a key enzyme for androgen and estrogen synthesis. The recently reported phase III trial in men who had previously received docetaxel reported a 4.6-month improvement in OS for patients receiving 10 mg prednisone daily and abiraterone when compared with prednisone alone [12, 13] . Abiraterone is also currently undergoing evaluation in a phase III trial in chemotherapy-naive patients (ClinicalTrial. gov identifier NCT00887198). Phase II data from multiple centres suggest that abiraterone may be more active when delivered before chemotherapy, with higher response rates and longer durations of response compared with postchemotherapy [14] [15] [16] [17] . These data suggest that there may be a common mechanism of action and cross-resistance between abiraterone and taxanes. We hypothesized that the antitumour activity and clinical benefit from docetaxel following treatment with abiraterone would be reduced. We therefore retrospectively evaluated the clinical antitumour activity of docetaxel in patients previously treated with abiraterone.
materials and methods eligibility
Patients with mCRPC treated in the Royal Marsden NHS Foundation Trust (RM) within the first-in-man continuous dosing phase I/II clinical study (COU-001; previously reported [14] ) were identified and their records accessed through the RM computer database. Patients with evidence of disease progression on abiraterone who proceeded to receive docetaxel were selected and their data were analysed. All patients enrolled in the phase I/II abiraterone study were required to have castrate levels of testosterone and castration was maintained with luteinizing hormone-releasing hormone agonists during subsequent therapies. All patients had Eastern Cooperative Oncology Group performance status of zero to two before starting docetaxel. Initiation of treatment with docetaxel followed standard clinical practice guidelines, including the requirement for adequate haematological, hepatic and renal function. Prognostic factors and risk groups as described by Armstrong et al. [18] were identified.
treatment plan and evaluations
Docetaxel was administered i.v. at the standard dose of 75 mg/m 2 every 3 weeks as a 1-h infusion with dexamethasone prophylaxis and oral prednisolone 5 mg twice daily as described previously [3] . Docetaxel dose was reduced for toxicity according to standard protocol. A baseline medical history and physical examination were performed on all patients. Blood tests, including PSA, were measured every three weeks, and radiological assessments, including computed tomography scans of the thorax, abdomen and pelvis and bone scans, were carried out every 3 to 6 months. Follow-up data, including time to progression and date of death, were available for all patients.
outcome measures PSA response rates were measured using Prostate Cancer Working Group 2 (PCWG 2) criteria [19, 20] . As recommended by the PCWG 2, PSA response was defined as 50% declines from baseline and a 25% increase confirmed with a second PSA reading a minimum of 3 weeks later was used to determine PSA progression and response duration. In line with PCWG 2 criteria, waterfall plots with maximum PSA change were constructed. RECIST v 1.0 [21] was used to assess soft tissue disease. Progression of bone disease was defined using PCWG 2 criteria, namely a confirmed increase of at least two new lesions on bone scan. Median OS was measured from the start of docetaxel treatment to death or censoring on 2 December 2010. Median time to PSA progression was the time from start of docetaxel therapy until PSA progression as defined by PCWG 2 criteria. Survival and PSA progression were calculated using Kaplan-Meier estimates (using Stata v 10.1, StataCorp LP, Texas, USA). Statistical analysis as defined in the text was used to test the null hypothesis that response to docetaxel in previously abiraterone-refractory patients was 33%, equal to our observed proportion in abiraterone-sensitive patients. (Table 2 and  Supplemental Table S1 , available at Annals of Oncology online, 'group 1'). Overall, 27 patients achieved a ≥50% PSA decline with abiraterone (Table 2 and Supplemental Table S1 , available at Annals of Oncology online, 'groups 2 and 3'). Thirty-four of the 35 patients progressed by PSA while on abiraterone, and one patient had solely evidence of radiological disease progression. Docetaxel was commenced mainly for progressive bone disease on imaging (in 20 patients; 57% of cohort) with worsening of pain in 16 patients (46% of cohort).
docetaxel dose intensity delivered
All patients started on the planned dose of 75 mg/m 2 docetaxel every 3 weeks. The median number of docetaxel courses administered was six (range: 2-12); the median duration of treatment was 5 months. Six patients (19%) had a dose reduction, five due to grade 3 or 4 neutropenia and one for nausea and vomiting. Six patients (19%) required a dose delay with a median delay of 13 days (range: 7-21 days): two patients due to docetaxel toxicity (one developed grade 3 transaminitis and the other grade 3 fatigue), one patient developed grade 3 hyperglycaemia and a urinary tract infection requiring hospital admission and one patient was delayed after cycle 1 to accommodate radiotherapy treatment for nerve root compression and subsequently only received a further cycle of treatment due to declining performance status. Two patients had a treatment delay for unrelated reasons (holiday and routine urinary stent change). Nine patients received at least 10 cycles (one patient received 12), correlating with planned docetaxel treatment delivery in 26% of patients. Docetaxel was discontinued due to poor performance status and/or rising PSA in 22 patients (Supplemental Table S1 , available at Annals of Oncology online) and due to radiological progression in six patients. Nine of 35 patients progressed by or at 12 weeks, mainly with PSA progression, but including four patients with both PSA and radiological progression. The total dose intensity achieved in our cohort was 79%; for patients who progressed before or at 12 weeks, it was 55%.
docetaxel antitumour activity post-abiraterone
All of the patients who failed to achieve a ≥50% PSA fall on abiraterone were subsequently docetaxel-refractory (N = 8; Table 2 and Supplemental Table S1 , available at Annals of Oncology online, group 1). PSA falls by ≥50% were recorded in nine patients [26%, 95% confidence interval (CI) 13% to 43%]. A PSA decline of ≥30% was achieved by 13 patients (37%, 95% CI 22% to 55%): 36% of good-risk group, 47% of intermediaterisk group and none of the patients from the poor-risk group. The median time to PSA progression was 4.6 months (95% CI 4.2-5.9) as shown in Figure 1B . Of the 24 patients assessable radiologically, 4 (11%) attained confirmed partial responses (PR), none of whom were abiraterone-refractory. The PR was associated with a decline in ≥50% PSA in three patients. Median OS was 12.5 months (95% CI 10.6-19.4) ( Figure 1A) . A waterfall plot of maximal PSA change is shown in Figure 2 . There were 13 patients with no PSA decline (37%). Out of 27 patients who had a ≥50% PSA decline with abiraterone, 9 had a ≥50% PSA decline with docetaxel (30%; Table 2 and  Supplemental Table S1 , available at Annals of Oncology online, 'group 2') and 18 did not (60%; Table 2 and Supplemental  Table S1 , available at Annals of Oncology online, 'group 3') (Supplemental Figure S1 , available at Annals of Oncology online). The null hypothesis that response to docetaxel in previously abiraterone-refractory patients is 33%, equal to the observed proportion in abiraterone-sensitive patients, may be rejected with borderline significance (two-sided P value = 0.05868, exact binomial test).
docetaxel tolerability post-abiraterone Docetaxel was well tolerated with no unexpected toxicity. The majority of reported side-effects were grade 1 and 2, as defined by Common Terminology Criteria for Adverse Events version 3.0. Grade 3/4 neutropenia was experienced by 14 patients (40%, 95% CI 24% to 58%). One patient developed grade 3 peripheral neuropathy following 10 cycles of docetaxel. Other grade 3 side-effects were vomiting (1), fatigue (1), diarrhoea (1), and depression (1). One patient died 25 days following cycle 2 possibly due a lower respiratory infection with a background of neutropenia.
discussion
In this study, we evaluated docetaxel activity, using PSA-based criteria and RECIST, in a consecutive group of 35 patients treated with abiraterone followed by docetaxel. To our knowledge, this is the first report describing response to docetaxel in patients treated with abiraterone. Comparing outcome parameters across different studies can be misleading, but the expected antitumour activity of three-weekly docetaxel and continuous prednisone as documented in the large phase III randomised TAX-327 study is a 45% rate of PSA fall by ≥50%, a 12% radiological response rate by RECIST and a median OS of 18.9 months [3] . To compare first-line treatment response in a similar group of patients to the ones reported in this study, we also evaluated the cohort of patients who received first-line docetaxel at our institution before participating in the COU-003 phase II study of postchemotherapy abiraterone [17] . This study accrued patients at the same time as the chemotherapy-naive COU-001 study reported in this manuscript: a ≥50% PSA decline was observed in 13 of 24 patients (54%), which was similar to the TAX327 data. In contrast, we here report a ≥50% PSA decline rate of 26% with docetaxel after abiraterone and a median time to PSA progression of 4.6 months and OS from commencement of docetaxel of only 12.5 months. These data could support the hypothesis that cross-resistance between these agents may exist and support preclinical evidence that the antitumour activity of docetaxel may be related to its impact on AR signalling. Moreover, another explanation for our findings could be high intratumoral androgens in patients discontinuing abiraterone, reducing docetaxel antitumour activity. The possibility that docetaxel acts by suppressing AR expression and therefore interferes with AR function raises the likelihood that AR overexpression or mutation may also contribute to docetaxel resistance. This hypothesis merits further evaluation preclinically.
The activity of abiraterone similarly also appears to differ according to its sequencing with docetaxel. The antitumour activity of abiraterone post-docetaxel was established in the abiraterone phase III study published this year [12] . Of 797 patients receiving abiraterone and prednisone, ≥50% PSA responses were documented in 29% of patients, with an overall response rate by RECIST of 14% and median OS of 14.8 months. Unfortunately, patients were not stratified according to prior response to docetaxel. Previous phase II data in the post-chemotherapy setting showed ≥50% PSA declines in 36%-51% participants [16, 17] . Although data from the phase III trial of pre-chemotherapy abiraterone acetate are awaited, phase II data suggest a markedly higher rate of ≥50% PSA declines. In our institution, we observed ≥50% PSA declines in 28 (67%) of 42 patients and PR by RECIST in 37.5% of the 24 patients with measurable disease [14] . In the other prechemotherapy phase II trial, ≥50% PSA declines were observed in 26 of 33 (79%) patients and time to PSA progression was 16.3 months [15] . These data indicate that abiraterone is more active pre-docetaxel and further supports the likelihood of cross-resistance between these agents.
It could be argued that the lower antitumour activity of docetaxel following abiraterone is a function of patients having more advanced disease; this, however, fails to explain the lack of impact of an active drug on the most frequently utilized measures of anticancer activity in this disease including PSA and soft tissue disease. One explanation for the disparate results could be an imbalance in baseline characteristics, but this seems unlikely considering the two cohorts. Although the baseline median PSA was lower in the TAX 327 cohort than in our study (114 compared with 232 ng/ml), visceral disease (which can carry a poorer prognosis) was more prevalent in the TAX 327 cohort (22% compared with 9% in our cohort). Moreover, using risk group stratification as described by Armstrong et al. [18] , the majority of patients in this report were in good-or intermediate-risk groups. We observed lower than expected PSA decline rates in each of the risk groups. Our data are limited by the small sample size, the retrospective nature of the study and as this is a single-institution experience. A prospective sequencing trial of abiraterone followed by docetaxel versus docetaxel followed by abiraterone could confirm our observations but would be challenging to perform due to the absence of suitable surrogates of response. 
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However, if abiraterone becomes available in the prechemotherapy setting, a confirmatory assessment of the response to sequential agents could be undertaken using prospectively collected data. 
